article thumbnail

A new dawn of the genomic age: five areas set to be transformed in 2023

pharmaphorum

2022 was a banner year for genomics. In March, the collaborative T2T consortium published the first complete telomere-to-telomere sequence of the human genome, filling in the last 8% of the 3 billion base pairs that make up our DNA.

Genome 129
article thumbnail

Investment fuels AI-driven development of breakthrough genomic medicines

pharmaphorum

David Del Bourgo (CEO and co-founder, Whitelab Genomics) has always been passionate about introducing disruptive, innovative technologies to markets. We founded Whitelab Genomics after realising the potential to use data, data science, and AI in a more systematic way to develop genomic therapies,” Del Bourgo says.

Genome 105
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Scientists use genomics to counter antimicrobial resistant typhoid

Drug Discovery World

Genome sequencing has been used to study typhoid fever in a study in Zimbabwe and understand how the disease has evolved to be resistant to treatment. In response, an emergency reactive vaccination campaign using Typhoid Conjugate Vaccine (TCV) was initiated in suburbs of Harare in 2019, providing moderate protection.

Genome 52
article thumbnail

Junk DNA: How the dark genome is changing RNA therapies

Drug Discovery World

The whole world realised the power of RNA when the Covid-19 pandemic brought us the first mRNA-based vaccines. Decoding ‘junk DNA’ The Human Genome Project and subsequent studies discovered that most of our DNA (approximately 98%) does not actually code for proteins, with humans having approximately 20,000 tox 25,000 protein-coding genes.

RNA 52
article thumbnail

Drug discovery hotspots: India’s Genome Valley

Drug Discovery World

India is traditionally known as ‘the pharmacy of the world’ due to its huge pharmaceuticals manufacturing capacity and high quantity of exports, particularly generic medicines and vaccines. Hyderabad is recognised as the vaccine hub of India. India’s domestic pharmaceutical market is expected to reach US$120-130 billion by 2030 2.

Genome 52
article thumbnail

CDSCO declares sample of Bharat Biotech’s typhoid vaccine Typbar as NSQ

AuroBlog - Aurous Healthcare Clinical Trials blog

The Central Drugs Standard Control Organisation (CDSCO) has declared a batch of Typbar, the typhoid polysaccharide vaccine from Bharat Biotech International Ltd as not of standard quality (NSQ).

article thumbnail

NHS England launches country-wide cancer vaccine trials

Drug Discovery World

Thousands of cancer patients in England are set to gain fast-tracked access to trials of mRNA personalised cancer vaccines following the launch of an NHS trial ‘matchmaking’ service to help find new life-saving treatments.